ArticleMolecular cancer research : MCR2010
Prostaglandin E receptor EP1 suppresses breast cancer metastasis and is linked to survival differences and cancer disparities.
Article in Molecular cancer research : MCR, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 47 citations in OpenAlex.
- The Role of Prostaglandins as Major Inflammatory Mediators in Colorectal Cancer.International journal of molecular sciences · 2025Review
- Arachidonic acid in aging: New roles for old players.Journal of advanced research · 2025Review
- Prostaglandin Pathways: Opportunities for Cancer Prevention and Therapy.Cancer research · 2022Review
- Review
- Cyclooxygenase-2 expression is associated with chemoresistance through cancer stemness property in hypopharyngeal carcinoma.Oncology letters · 2021Article
- Breast adipose tissue macrophages (BATMs) have a stronger correlation with breast cancer survival than breast tumor stroma macrophages (BTSMs).Breast cancer research : BCR · 2021Article
- EP3 Is an Independent Prognostic Marker Only for Unifocal Breast Cancer Cases.International journal of molecular sciences · 2020Article
- EP4 and Class III β-Tubulin Expression in Uterine Smooth Muscle Tumors: Implications for Prognosis and Treatment.Cancers · 2019Article
- EP3 receptor antagonist L798,106 reduces proliferation and migration of SK-BR-3 breast cancer cells.OncoTargets and therapy · 2019Article
- EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer.BMC cancer · 2018Article
- Prostaglandin E2 receptor EP1 in healthy and diseased human endometrium.Histochemistry and cell biology · 2018Article
- Regulation of inflammation by lipid mediators in oral diseases.Oral diseases · 2017Review
- Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets?British journal of pharmacology · 2015Review
- COX-2 induces lytic reactivation of EBV through PGE2 by modulating the EP receptor signaling pathway.Virology · 2015Article
- Association of EP2 receptor and SLC19A3 in regulating breast cancer metastasis.American journal of cancer research · 2015Article
- Microenvironmental Influences on Metastasis Suppressor Expression and Function during a Metastatic Cell's Journey.Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2014Article
- Prostaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like properties.Breast cancer research and treatment · 2014Article
- Prostaglandin receptors EP1-4 as a potential marker for clinical outcome in urothelial bladder cancer.American journal of cancer research · 2014Article
- Non-steroid anti-inflammatory drugs, prostaglandins, and cancer.Cell & bioscience · 2013Article
- Autocrine prostaglandin E2 signaling promotes tumor cell survival and proliferation in childhood neuroblastoma.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
Cyclooxygenase-2 is frequently overexpressed and associated with poor prognosis in breast cancer. The cyclooxygenase-2 product prostaglandin E(2) elicits cellular responses through four G-protein-coupled receptors, designated EP1 to EP4, coupled to distinct intracellular signaling pathways. EP4, expressed on malignant breast cells, promotes metastasis; however, a role for EP1 in metastasis has not been investigated. Using a murine model of metastatic breast cancer, we now show that pharmacologic antagonism of EP1 with SC19220 or AH6809 promoted lung colonization of mammary tumor cells by 3.7- to 5.4-fold. Likewise, reducing EP1 gene expression by shRNA also increased metastatic capacity relative to cells transfected with nonsilencing vector but did not affect the size of transplanted tumors. Examination of invasive ductal carcinomas by immunohistochemistry shows that EP1 was detected in both the cytoplasm and nucleus of benign ducts as well as malignant cells in some samples, but was absent or limited to either the nucleus or cytoplasm in other malignant samples. Overall survival for women with tumors that were negative for nuclear EP1 was significantly worse than for women with EP1 expression (P = 0.008). There was no difference in survival for women with differences in cytoplasmic EP1 expression (P = 0.46). Comparing EP1 mRNA in breast tumors from African American and European American women revealed that many more African American breast tumors lacked detectable EP1 mRNA (P = 0.04). These studies support the hypothesis that EP1 functions as a metastasis suppressor and that loss of nuclear EP1 is associated with poorer overall survival and may contribute to disparities in outcome in different populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.